CGEN:NASDAQ
Compugen Ltd
$1.98
arrow_upward
+0.77%(+0.015) 1D
Oct 19, 11:21:57 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CGEN...
Open
$1.97
High
$1.99
Low
$1.95
Mkt. cap
187.09M
Avg. vol.
184.54K
Volume
45.74K
P/E ratio
5.44
52-wk high
$3.24
52-wk low
$1.43
EPS
$0.36
Beta
2.78
Shares outstanding
94.73M
No. of employees
75
Open
$1.97
High
$1.99
Low
$1.95
Mkt. cap
187.09M
Avg. vol.
184.54K
Volume
45.74K
P/E ratio
5.44
52-wk high
$3.24
52-wk low
$1.43
EPS
$0.36
Beta
2.78
Shares outstanding
94.73M
No. of employees
75
News stories
From web sources and news partners
HDFC Sky
·
31 minutes ago
Nasdaq Jumps 259 Points to 26,399 as Intel Surges 5.5% and AI Stocks Rebound After Brutal Selloff
TipRanks
·
24 minutes ago
Dow Jones Steady as AI Stocks Rebound from Selloff
TradingView
·
1 hour ago
The Dow Jones Index Opens 0.08% Lower
Seeking Alpha
·
1 hour ago
The Bull Market Isn’t Sick Anymore (NYSEARCA:SPY)
Profile
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. Wikipedia
About Compugen Ltd